AI assistant
AbbVie Inc. — Director's Dealing 2022
Jul 8, 2022
29755_dirs_2022-07-08_5791d7f7-5b46-489b-9011-88c4bb5de9e2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2022-06-28
Reporting Person: Reents Scott T (N/A)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock, $0.01 par value | 809 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option (Right to buy) | $61.36 | 2028-02-15 | Common Stock (14140) | Direct | |
| Option (Right to buy) | $114.36 | 2028-02-14 | Common Stock (11810) | Direct | |
| Option (Right to buy) | $79.02 | 2029-02-20 | Common Stock (19470) | Direct | |
| Option (Right to buy) | $93.50 | 2030-02-19 | Common Stock (28641) | Direct | |
| Option (Right to buy) | $105.92 | 2031-02-17 | Common Stock (15527) | Direct | |
| Option (Right to buy) | $144.54 | 2032-02-16 | Common Stock (11383) | Direct |
Footnotes
F1: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 4,714 shares on 2/16/2018, as to 4,713 shares on 2/16/2019 and as to 4,713 shares on 2/16/2020.
F2: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 3,936 shares on 2/15/2019, as to 3,937 shares on 2/15/2020 and as to 3,937 shares on 2/15/2021.
F3: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 6,490 shares on 2/21/2020, as to 6,490 shares on 2/21/2021 and as to 6,490 shares on 2/21/2022.
F4: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 9,547 shares on 2/20/2021, as to 9,547 shares on 2/20/2022 and will become exercisable as to 9,547 shares on 2/20/2023.
F5: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 5,176 shares on 2/18/2022, and will become exercisable as to 5,176 shares on 2/18/2023 and as to 5,175 shares on 2/18/2024.
F6: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 3,794 shares on 2/17/2023, as to 3,794 shares on 2/17/2024 and as to 3,795 shares on 2/17/2025.